Talis Biomedical (TLIS) - Earnings per share increase in current year

The relative EPS YoY trend helps assess the capital management efficiency of Talis Biomedical (TLIS). A fabless analyzer assembly model in the US ensures supply stability, while the 0.00 metric determines this level. Growth is constrained by strict FDA requirements and patent barriers. Meanwhile, low geopolitical pressure and the humanitarian status of the equipment guarantee the company's resilience across trade channels.

talis.bio (TLIS): Earnings growth in current year from 07/04/2022 to 09/07/2024

Financial and market metric breakdowns for talis.bio (TLIS)

- price and consensus price forecast:

Stock Quotes Talis Biomedical Corporation|TLIS - Consensus Target

- market capitalization indicators:

Market Value Talis Biomedical Corporation|TLIS - Total Company Value

- business book valuation details:

Accounting Value per Share Talis Biomedical|TLIS - Book Capitalization|Market-to-Book Ratio talis.bio|TLIS - Company Total Assets

- debt and liquidity details:

- net income and valuation ratios data:

TLIS - Net Income|Expected Net Income Talis Biomedical|TLIS - P/E Multiple|Projected Price to Earnings Ratio Talis Biomedical Corporation|TLIS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple Talis Biomedical Corporation|TLIS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Talis Biomedical|TLIS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months talis.bio|TLIS - Earnings per share growth in current year|Net earnings per share change forecast for next year Talis Biomedical

Fundamental valuation:TLIS, Talis Biomedical Corp

Talis Biomedical (TLIS) monetizes its Talis One rapid diagnostic technology, reducing molecular test result turnaround times to 30 minutes. This trend is reflected in the calculation of the percentage change in net income per share, which measures the real efficiency of business scaling. Analyzing the annual earnings per share growth indicator allows investors to filter out market noise and determine the company's fundamental margin of safety.

Direct competitors